CRISPR Therapeutics AG (NASDAQ:CRSP) and Acer Therapeutics Inc. (NASDAQ:ACER) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CRISPR Therapeutics AG||60||0.00||34.37M||-0.46||0.00|
|Acer Therapeutics Inc.||3||0.00||3.46M||-3.25||0.00|
We can see in table 1 the earnings per share, gross revenue and valuation of CRISPR Therapeutics AG and Acer Therapeutics Inc.
Table 2 demonstrates the net margins, return on equity and return on assets of CRISPR Therapeutics AG and Acer Therapeutics Inc.
|Net Margins||Return on Equity||Return on Assets|
|CRISPR Therapeutics AG||57,388,545.67%||-2.6%||-2%|
|Acer Therapeutics Inc.||101,493,062.69%||-98.3%||-87.3%|
The current Quick Ratio of CRISPR Therapeutics AG is 8.3 while its Current Ratio is 8.3. Meanwhile, Acer Therapeutics Inc. has a Current Ratio of 7.1 while its Quick Ratio is 7.1. CRISPR Therapeutics AG is better positioned to pay off its short-term and long-term debts than Acer Therapeutics Inc.
Recommendations and Ratings for CRISPR Therapeutics AG and Acer Therapeutics Inc. can be find in next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|CRISPR Therapeutics AG||0||0||3||3.00|
|Acer Therapeutics Inc.||0||0||0||0.00|
CRISPR Therapeutics AG’s upside potential is 10.16% at a $72 average price target.
Insider and Institutional Ownership
Institutional investors owned 46.8% of CRISPR Therapeutics AG shares and 55.1% of Acer Therapeutics Inc. shares. About 0.4% of CRISPR Therapeutics AG’s share are owned by insiders. Insiders Competitively, owned 0.2% of Acer Therapeutics Inc. shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|CRISPR Therapeutics AG||1%||49.37%||59.3%||63.07%||101.48%||153.31%|
|Acer Therapeutics Inc.||5.46%||13.62%||26.12%||-77.4%||-82.52%||-81.76%|
For the past year CRISPR Therapeutics AG has 153.31% stronger performance while Acer Therapeutics Inc. has -81.76% weaker performance.
CRISPR Therapeutics AG beats on 8 of the 10 factors Acer Therapeutics Inc.
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Acer Therapeutics Inc. develops therapies for the treatment of serious ultra-rare diseases with critical unmet medical needs. The company offers Celiprolol for vascular ehlers-danlos syndrome and ACER-001 for maple syrup urine disease (MSUD). It also offers advancing ACER-001 for the treatment of urea cycle disorders (UCD). The company was founded in 2013 and is based in Cambridge, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.